logo-loader

Lumos Diagnostics expands European reach with new FebriDx distribution agreement in Portugal

Published: 10:03 19 Nov 2026 AEDT

Lumos Diagnostics Holdings Ltd - Lumos Diagnostics expands European reach with new FebriDx distribution agreement in Portugal

Lumos Diagnostics Holdings Ltd (ASX:LDX, OTC:LDXHF) has strengthened its European commercial network after securing a new distribution agreement with Portuguese medical device supplier Magnamed LDA for its FebriDx rapid diagnostic test.

The non-exclusive agreement gives Lumos access to Magnamed’s established network of more than 300 customers across Portugal, including primary care providers, urgent care facilities and hospitals.

Magnamed has already placed an initial stocking order, enabling immediate product availability for its customers and supporting Lumos’ strategy to increase FebriDx adoption across European healthcare markets.

Managing director Doug Ward said the latest agreement would support the company's expansion ambitions.

“We are pleased to further expand our European distribution network with Magnamed in Portugal. Building on our existing relationships across the region, this partnership will help broaden access to FebriDx® and support our continued commercial growth across Europe.”

Established distribution network supports expansion

Founded in 1996, Magnamed supplies medical equipment and consumables to public and private healthcare providers throughout Portugal.

The company represents several international healthcare brands and operates an established sales, logistics and product support network.

Under the agreement, Magnamed will distribute FebriDx through its existing customer relationships, providing Lumos with an additional commercial channel in the Portuguese market.

The partnership builds on Lumos’ growing European distribution footprint, which includes agreements covering the UK, Greece, Romania, the Baltic states, the Netherlands, Spain and Portugal.

Lumos further strengthened its European network in July 2026 through the addition of Alpha Medical.

The latest agreement broadens the company's distribution coverage within Portugal as it pursues further commercial growth across Europe.

FebriDx commercialisation gains momentum

FebriDx forms part of Lumos’ portfolio of rapid, point-of-care diagnostic technologies designed to support clinical decision-making.

The company's European strategy centres on partnerships with established regional distributors that can introduce its products to healthcare providers through existing sales channels.

The Portuguese distribution agreement follows further commercial progress in the US, where Lumos is expanding the rollout of FebriDx across another 97 WellStreet Urgent Care locations, bringing the number of participating clinics to 141 across Ohio, Georgia and Michigan. Once implemented, the expansion will lift the total number of US sites using FebriDx to 365.

The expansion follows a successful pilot that demonstrated improvements in clinical decision-making and antibiotic stewardship. WellStreet operates more than 200 urgent care clinics and manages over one million acute respiratory infection presentations annually. The network plans to introduce FebriDx across all its clinics, providing Lumos with a significant opportunity to increase test volumes and strengthen its US commercial presence.

Small Cap Snapshot: Firefly, Krakatoa, Dalaroo, Beetaloo and more...

Here’s a look at some of the small-cap companies making news this Monday.FireFly Metals has continued to build momentum at its Green Bay copper-gold project in Canada, extending the high-grade core zone with drilling that has intersected mineralisation outside the current resource and closer to...

1 week, 4 days ago